Benzothiazol-2-yl-piperidin-4-ylmethyl-amine | 521273-79-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 英文名称: Benzothiazol-2-yl-piperidin-4-ylmethyl-amine
• 英文别名: N-(4-Piperidinylmethyl)-2-benzothiazolamine；N-(piperidin-4-ylmethyl)-1,3-benzothiazol-2-amine
• CAS: 521273-79-0
• 化学式: C₁₃H₁₇N₃S
• 分子量: 247.364
• InChiKey: ASBKSUFXPNFZFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  65.2
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (+/-)-1-[3,5-bis-(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinone 、 Benzothiazol-2-yl-piperidin-4-ylmethyl-amine 生成
  参考文献：
  名称：

  1-(1,2-disubstituted pipeidinyl)-4-substituted piperidine derivatives

  摘要：

  本发明涉及以下式的化合物 其中n为0、1或2；m为1或2，但如果m为2，则n为1；p为0、1或2；═Q为═O或═NR3；X为配位键或式的二价基团—O—、—S—、—NR3—；R1为Ar1；Ar1C1-6烷基或二(Ar1)C1-6烷基，其中每个C1-6烷基基团可选择地用羟基、C1-4烷氧基、氧代基或式的缩醛基团取代—O—CH2—CH2—O—或—O—CH2—CH2—CH2—O—；R2为Ar2；Ar2C1-6烷基；Het或HetC1-6烷基；R3为氢或C1-6烷基；R4为氢；C1-4烷基；C1-4烷氧基C1-4烷基；羟基C1-4烷基；羧基；C1-4烷氧羰基或Ar3；R5为氢；羟基；Ar3；Ar3C1-6烷氧基；二(Ar3)C1-6烷氧基；Ar3C1-6烷硫基；二(Ar3)C1-6烷硫基；Ar3C1-6烷磺氧基；二(Ar3)C1-6烷磺氧基；Ar3C1-6烷磺基；二(Ar3)C1-6烷磺基；—NR7R8；用—NR7R8取代的C1-6烷基；或式的基团(a-1)或(a-2)；R4和R5也可结合在一起；R6为羟基；C1-6烷氧基；C1-6烷基或Ar3C1-6烷基；Ar1、Ar2和Ar3为苯基或取代苯基；Ar2也为萘基；Het为可选择地取代的单环或双环杂环；作为P物质拮抗剂；它们的制备、含有它们的组合物以及它们作为药物的用途。

  公开号：

  US06346540B1

文献信息

• Highly potent and selective αVβ3-receptor antagonists: solid-phase synthesis and SAR of 1-substituted 4-amino-1H-pyrimidin-2-ones
  作者：Christian Zechel、Gisela Backfisch、Jürgen Delzer、Hervé Geneste、Claudia Graef、Wilfried Hornberger、Andreas Kling、Udo E.W Lange、Arnulf Lauterbach、Werner Seitz、Thomas Subkowski

  DOI：10.1016/s0960-894x(02)00931-9

  日期：2003.1

  Solid-phase synthesis and SAR of alpha(V)beta(3)-receptor antagonists based on a NI-substituted 4-amino-1H-pyrimidin-2-one scaffold are described. The most potent compounds exhibited IC50 values towards alpha(V)beta(3) in the nano- to subnanomolar range and high selectivity versus related integrins like alpha(IIb)beta(3). For selected examples efficacy in functional cellular assays was demonstrated. (C) 2002 Published by Elsevier Science Ltd.
• JANSSENS, FRANS E.;VAN, OFFENWERT THEOPHILUS T. J. M.;STOKBROEKX, RAYMOND+
  作者：JANSSENS, FRANS E.、VAN, OFFENWERT THEOPHILUS T. J. M.、STOKBROEKX, RAYMOND+

  DOI：——

  日期：——
• 1-(1,2-disubstituted pipeidinyl)-4-substituted piperidine derivatives
  申请人：Janssen Pharmaceutica N.V.

  公开号：US06346540B1

  公开（公告）日：2002-02-12

  The present invention concerns compounds of formula the N-oxide forms, the pharmaceutically acceptable addition salts and stereochemically isomeric forms thereof, wherein n is 0, 1 or 2; m is 1 or 2, provided that if m is 2, then n is 1; p is 0, 1 or 2; ═Q is ═O or ═NR3; X is a covalent bond or a bivalent radical of formula —O—, —S—, —NR3—; R1 is Ar1; Ar1C1-6alkyl or di(Ar1)C1-6alkyl, wherein each C1-6alkyl group is optionally substituted with hydroxy, C1-4alkyloxy, oxo or a ketalized oxo substituent of formula —O—CH2—CH2—O— or —O—CH2—CH2—CH2—O—; R2 is Ar2; Ar2C1-6alkyl; Het or HetC1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 is hydrogen; C1-4alkyl; C1-4alkyloxyC1-4alkyl; hydroxyC1-4alkyl; carboxyl; C1-4alkyloxycarbonyl or Ar3; R5 is hydrogen; hydroxy; Ar3; Ar3C1-6alkyloxy; di(Ar3)C1-6alkyloxy; Ar3C1-6alkylthio; di(Ar3)C1-6alkylthio; Ar3C1-6alkylsulfoxy; di(Ar3)C1-6alkylsulfoxy; Ar3C1-6alkylsulfonyl; di(Ar3)C1-6alkylsulfonyl; —NR7R8; C1-6alkyl substituted with —NR7R8; or a radical of formula (a-1) or (a-2); R4 and R5 may also be taken together; R6 is hydroxy; C1-6alkyloxy; C1-6alkyl or Ar3C1-6alkyl; Ar1, Ar2 and Ar3 are phenyl or substituted phenyl; Ar2 is also naphtalenyl; and Het is an optionally substituted monocyclic or bicyclic heterocycle; as substance P antagonists; their preparation, compositions containing them and their use as a medicine.

  本发明涉及以下式的化合物 其中n为0、1或2；m为1或2，但如果m为2，则n为1；p为0、1或2；═Q为═O或═NR3；X为配位键或式的二价基团—O—、—S—、—NR3—；R1为Ar1；Ar1C1-6烷基或二(Ar1)C1-6烷基，其中每个C1-6烷基基团可选择地用羟基、C1-4烷氧基、氧代基或式的缩醛基团取代—O—CH2—CH2—O—或—O—CH2—CH2—CH2—O—；R2为Ar2；Ar2C1-6烷基；Het或HetC1-6烷基；R3为氢或C1-6烷基；R4为氢；C1-4烷基；C1-4烷氧基C1-4烷基；羟基C1-4烷基；羧基；C1-4烷氧羰基或Ar3；R5为氢；羟基；Ar3；Ar3C1-6烷氧基；二(Ar3)C1-6烷氧基；Ar3C1-6烷硫基；二(Ar3)C1-6烷硫基；Ar3C1-6烷磺氧基；二(Ar3)C1-6烷磺氧基；Ar3C1-6烷磺基；二(Ar3)C1-6烷磺基；—NR7R8；用—NR7R8取代的C1-6烷基；或式的基团(a-1)或(a-2)；R4和R5也可结合在一起；R6为羟基；C1-6烷氧基；C1-6烷基或Ar3C1-6烷基；Ar1、Ar2和Ar3为苯基或取代苯基；Ar2也为萘基；Het为可选择地取代的单环或双环杂环；作为P物质拮抗剂；它们的制备、含有它们的组合物以及它们作为药物的用途。